BiomX Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 17, 2025, covers the results of BiomX Inc.'s 2025 Annual Meeting of Stockholders held on October 16, 2025. The company is incorporated in Delaware and maintains its principal executive offices in Ness Ziona, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted in favor of all three proposals presented at the annual meeting:
- Proposal 1 (Election of Directors): Stockholders elected three Class II directors (Susan Blum, Dr. Jesse Goodman, and Gregory Merril) to serve until the 2028 annual meeting. While all were approved, Dr. Goodman and Gregory Merril received a higher number of withheld votes compared to Susan Blum.
- Proposal 2 (Reverse Stock Split Authorization): Stockholders authorized the Board of Directors to amend the certificate of incorporation to effect a reverse stock split of outstanding Common Stock at any ratio between at least 1-for-5 and less than 1-for-20.
- Proposal 3 (Auditor Ratification): Stockholders ratified the selection of Kesselman & Kesselman, certified public accountants (Isr.), as the independent registered public accounting firm for fiscal year 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies. The document serves solely to disclose the final voting results of the annual meeting.
Key Facts for Investor Verification
- Verify the specific ratio and timing for the authorized reverse stock split, as the Board now has discretion to act within the 1-for-5 to 1-for-20 range.
- Review the composition of the Board of Directors following the election of the three new Class II directors.
- Confirm the implementation date of the reverse stock split, if and when the Board exercises its newly granted authority.